Identifying Neuroimaging Markers of Neuroinflammation in Neurodegenerative Diseases
Not yet recruiting
- Conditions
- Huntington's Disease
- Registration Number
- ACTRN12617000721303
- Lead Sponsor
- Monash University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Not yet recruiting
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What neuroimaging markers correlate with neuroinflammation in Huntington's disease using PET-MRI fusion techniques?
How do neuroinflammatory biomarkers identified in ACTRN12617000721303 compare to standard Huntington's disease progression indicators?
What molecular pathways in Huntington's disease are most associated with neuroinflammation as observed through in vivo PET-MRI imaging?
Are there specific neuroimaging patterns in Huntington's disease that predict response to anti-inflammatory therapeutic interventions?
What are the implications of neuroinflammation markers from ACTRN126170007211303 for developing disease-modifying therapies in Huntington's disease?